enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Trastuzumab - Wikipedia

   en.wikipedia.org/wiki/Trastuzumab

   Trastuzumab, sold under the brand name Herceptin among others, is a monoclonal antibody used to treat breast cancer and stomach cancer. [ 31 ] [ 28 ] [ 32 ] [ 33 ] It is specifically used for cancer that is HER2 receptor positive . [ 31 ]

3. Trastuzumab/hyaluronidase - Wikipedia

   en.wikipedia.org/wiki/Trastuzumab/hyaluronidase

   Clinical trial number NCT01566721 for "A Safety and Tolerability Study of Assisted and Self-Administered Subcutaneous (SC) Herceptin (Trastuzumab) as Adjuvant Therapy in Early Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer (SafeHER)" at ClinicalTrials.gov

4. Trastuzumab deruxtecan - Wikipedia

   en.wikipedia.org/wiki/Trastuzumab_deruxtecan

   Trastuzumab deruxtecan, sold under the brand name Enhertu, is an antibody-drug conjugate consisting of the humanized monoclonal antibody trastuzumab (Herceptin) covalently linked to the topoisomerase I inhibitor deruxtecan (a derivative of exatecan). [11] [12] It is licensed for the treatment of breast cancer or gastric or gastroesophageal ...

5. TCH (chemotherapy) - Wikipedia

   en.wikipedia.org/wiki/TCH_(chemotherapy)

   TCH is a chemotherapy regimen consisting of Taxotere (docetaxel), carboplatin and Herceptin (trastuzumab), which is used to treat breast cancer. References

6. Trastuzumab emtansine - Wikipedia

   en.wikipedia.org/wiki/Trastuzumab_emtansine

   Each molecule of trastuzumab emtansine consists of a single trastuzumab molecule with several molecules of DM1, a cytotoxic maytansinoid, attached. [21] SMCC, or succinimidyl trans -4-(maleimidylmethyl)cyclohexane-1-carboxylate, is a heterobifunctional crosslinker , a type of chemical reagent that contains two reactive functional groups , a ...

7. Mylan (MYL) Launches Herceptin Biosimilar Ogivri in the US - AOL

   www.aol.com/news/mylan-myl-launches-herceptin...

   Mylan (MYL) launches Ogivri, a biosimilar of Roche's blockbuster breast cancer drug, Herceptin (trastuzumab), in the United States.

8. FDA Approves Genentech's Kadcyla (Ado-Trastuzumab ... - AOL

   www.aol.com/news/2013-02-22-fda-approves-genen...

   FDA Approves Genentech's Kadcyla (Ado-Trastuzumab Emtansine), the First Antibody-Drug Conjugate for Treating HER2-Positive Metastatic Breast Cancer -- New Personalized Medicine Helped People in ...

9. Pertuzumab/trastuzumab/hyaluronidase - Wikipedia

   en.wikipedia.org/wiki/Pertuzumab/trastuzumab/...

   The fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase was approved for medical use in the United States in June 2020. [5] [10]The FDA's approval was based on the results of a non-inferiority study in participants with HER2-positive early breast cancer, which demonstrated the fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase had comparable efficacy and ...